OR WAIT null SECS
With this investment into Yapan Bio, Piramal Pharma adds new technologies and capabilities in large molecules, including vaccines and gene therapies, to its global offering.
Piramal Pharma Limited (PPL) has invested INR101.77cr (US$13.7 million) in Hyderabad, India-based Yapan Bio to augment its contract development and manufacturing organization (CDMO) business, Piramal Pharma Solutions (PPS). With this investment, PPL holds a 27.78% equity stake in Yapan Bio.
The acquisition adds to PPS’ capabilities in developing and manufacturing large molecules for human clinical trials, the company stated in a Dec. 21, 2021 press release. Yapan Bio adds process development, scale-up, and current good manufacturing practice (CGMP)-compliant manufacturing of vaccines and biologics/biotherapeutics, including high-containment product classes (up to biosafety level-2+ [BSL-2+]), recombinant vaccines, RNA/DNA vaccines, gene therapies, monoclonal antibodies, therapeutic proteins, and other complex biologics.
The biologics capabilities that Yapan Bio offers can be synergistic with PPS’ antibody-drug conjugation capabilities, specifically benefitting customers who prefer an integrated program that includes development, manufacturing, conjugation, and fill/finish. PPS currently offers integrated payload, conjugation, and fill/finish services, which will now be enhanced with the addition of antibody capabilities from Yapan Bio.
“During the past decade, biologics and their accompanying development services are the fastest growing segments of the CDMO market. This investment, coupled with the market-leading capabilities of our Grangemouth, UK, site in antibody-drug conjugations and our sterile fill/finish capabilities in Lexington, [Mass.] [in the United States], demonstrates our commitment to growing our service offerings in the large-molecule CDMO space,” said Peter DeYoung, CEO, Pharma Solutions, Piramal Pharma Limited, in the press release.
Source: Piramal Pharma Solutions